Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Tri-specific autologous CD19.20.22 chimeric antigen receptor (CAR) T-cells for patients with Relapsed/Refractory B-cell lymphomas.

Samuel Weeks, Aerielle Matsangos, Daniel Yamoah et al. Nov 03, 2025 pp. 4145-4145 10.1182/blood-2025-4145

Abstract Introduction: CD19-directed CAR T cell (CAR-T) therapy has curative potential for patients with relapsed/refractory (R/R) B-cell ly...

Role of anti-GP antibodies release with platelet-derived extracellular vesicles in regulating ITP platelet apoptosis

Fan Wenxuan, Gong Ying, Jian Baodan et al. Nov 03, 2025 pp. 4795-4795 10.1182/blood-2025-4795

Abstract Anti-glycoprotein(GP) antibodies-mediated platelet destruction has been recognized as the most typical pathogenesis of ITP. Our pre...

External validation of the intermountain risk scores for post-discharge (PD) thrombosis and bleeding in an independent population

Mansour Gergi, Katherine Wilkinson, Nicholas Roetker et al. Nov 03, 2025 pp. 2684-2684 10.1182/blood-2025-2684

Abstract Introduction: Extended pharmacologic thromboprophylaxis in medical patients has largely failed to demonstrate clinical benefit in m...

Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial

Shaun Patterson, Niamh Mannion, Claire McKeeve et al. Nov 03, 2025 pp. 5558-5558 10.1182/blood-2025-5558

Abstract Background: Chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) have excellent survival outcomes...

Talquetamab alters T cell transcriptome in presence of GPRC5D on MM cells

Umair Munawar, Alexander Leipold, Silvia Nerreter et al. Nov 03, 2025 pp. 5701-5701 10.1182/blood-2025-5701

Abstract Background: G protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as an important immune tar...

Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies

Tapan Kadia, Patricia Kropf, Michael Leahy et al. Nov 03, 2025 pp. 1641-1641 10.1182/blood-2025-1641

Abstract Introduction Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have poor prognoses. Venetoclax plus hypomethylating...

Distinguishing on-target efficacy and off-target toxicity with antibody drug conjugates (ADCs) on diseased and normal hematopoietic cells

Coranna Akdemirbey, Aisha Mergaert, Emer Clarke Nov 03, 2025 pp. 7010-7010 10.1182/blood-2025-7010

Abstract One of the challenges with ADC treatment is off-target toxicity to hematopoietic cells resulting in neutropenia, severe anemia and...

Field-level visual explanations for leukocyte classification using AI model: Enhancing interpretability in peripheral smear diagnostics

Manpreet Saini, Agampreet Saini, Jayvardhan Singh Negi et al. Nov 03, 2025 pp. 2573-2573 10.1182/blood-2025-2573

Abstract Introduction Despite notable advances in deep learning, the clinical integration of artificial intelligence (AI...

Real-world outcome of low-frequency outpatient monitoring for venetoclax initiation in CLL: Single-center experience

Monica Wallin, Sally Ko, Pratik Shah et al. Nov 03, 2025 pp. 7919-7919 10.1182/blood-2025-7919

Abstract Background: The treatment landscape for CLL/SLL has shifted from chemoimmunotherapy to targeted therapies, with BCL-2 inhibitors li...

Risk of venous thromboembolism associated with CDK 4/6 inhibitors and adjuvant hormonal therapy in non-metastatic breast cancer: A systematic review and meta-analysis

Elysa Cortez, Erick Torres Luna, Marcos Blancarte Ibarra et al. Nov 03, 2025 pp. 4909-4909 10.1182/blood-2025-4909

Abstract Background: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), non-metastatic breast cance...

Outcome disparities among survivors of hematologic malignancies diagnosed in childhood

Camila Pabon, Kelci Daniel, Veronica Garcia-Morales et al. Nov 03, 2025 pp. 2766-2766 10.1182/blood-2025-2766

Abstract Introduction: Latinos are a rapidly growing population in the Southwest U.S. Evidence has suggested population-based differences in...

Inhibition of DOCK1 prevents the clonal expansion of high-risk TP53-mutant clonal hematopoiesis induced by genotoxic stressors.

Yang Feng, Thomas Koehnke, Bolan Patrick et al. Nov 03, 2025 pp. 631-631 10.1182/blood-2025-631

Abstract Background: TP53-mutant clonal hematopoiesis (CH) is prevalent in populations that received genotoxic cancer therapy and is associa...

Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs

Xuezi Hu, Alan Aberdeen, Sharon Ruane et al. Nov 03, 2025 pp. 5599-5599 10.1182/blood-2025-5599

Abstract INTRODUCTION The myeloproliferative neoplasms (MPNs) are clonal haematological disorders that display significa...

Blood tells a hidden story: Von willebrand disease in the puzzle of refractory postpartum hemorrhage

Nasim Salimiaghdam, Ahmed Mustafa, Mojtaba Akhtari et al. Nov 03, 2025 pp. 6634-6634 10.1182/blood-2025-6634

Abstract Blood Tells a Hidden Story: Revealed Von Willebrand Disease in the Puzzle of Refractory Postpartum Hemorrhage Nasim Salimiaghdam1,...

Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD)

Ariela Noy, Robert Ohgami, Nikhil Munshi et al. Nov 03, 2025 pp. 2606-2606 10.1182/blood-2025-2606

Abstract Introduction: Idiopathic multicentric Castleman disease (iMCD) is a rare, cytokine-driven hematologic disorder characterized by dif...

Genomic and immune determinants of response to CD3 x CD20 bispecific antibodies in aggressive B-cell lymphoma

Xi Yang, Weiwei Zhang, Anamarija Perry et al. Nov 03, 2025 pp. 3542-3542 10.1182/blood-2025-3542

Abstract Introduction: CD3 x CD20 bispecific antibodies (BsAb)have been approved for use in relapsed/refractory (R/R) diffuse large B-cell ly...

Frontline therapy patterns and outcomes in chronic lymphocytic leukemia: A real-world, multicenter analysis from Latin America.

Celso Arrais-Rodrigues, Ana Oliver, Maria Cugliari et al. Nov 03, 2025 pp. 2775-2775 10.1182/blood-2025-2775

Abstract Background: Access to novel therapies for chronic lymphocytic leukemia (CLL) varies throughout Latin America. M...

National trends and disparities in AL amyloidosis-related mortality among multiple myeloma patients in the United States: A population-based study (1999–2023)

Haseeb Tareen, Allah Dad, Ali Zubair et al. Nov 03, 2025 pp. 2193-2193 10.1182/blood-2025-2193

Abstract Background: Immunoglobulin light chain (AL) amyloidosis is a multisystem disorder resulting from the deposition of misfolded monocl...

The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Keshu Zhou, Xingchen Liu, Xueli Jiao et al. Nov 03, 2025 pp. 1914-1914 10.1182/blood-2025-1914

Abstract Background: Patients (pts) with R/R DLBCL who failed with multi-agent therapy have a poor prognosis. MRG001 is a CD20-directed anti...

The silent foe: Agranulocytosis-related mortality in the United States from 1999 to 2023: Insights from the CDC wonder database

Hakim Wazir, Sandhya Rani Reddy, Nayanika Tummala et al. Nov 03, 2025 pp. 6553-6553 10.1182/blood-2025-6553

Abstract The Silent Foe: Agranulocytosis-Related Mortality in the United States from 1999 to 2023: Insights from the CDC Wonder Database Int...

Trial in progress: Phase I trial to evaluate safety of oral azacytidine in combination with pomalidomide as maintenance therapy in AML

Thomas Eipe, Manju Sengar, Hasmukh Jain et al. Nov 03, 2025 pp. 8251-8251 10.1182/blood-2025-8251

Abstract Background and Significance: Despite achieving complete remission with induction therapy, approximately 60% of...

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis

Vladimir Otasevic, Darko Antic, Kausik Maiti MD et al. Nov 03, 2025 pp. 6315-6315 10.1182/blood-2025-6315

Abstract Introduction: Covalent Bruton tyrosine kinase inhibitors (BTKis) have revolutionized the treatment of chronic lymphocytic leukemia...

Mortality trends in chronic myeloid leukemia in the United States: A population-based analysis

Michael Roberts, Humna Younis, Faisal Riaz et al. Nov 03, 2025 pp. 7289-7289 10.1182/blood-2025-7289

Abstract Introduction Chronic Myeloid Leukemia (CML) accounts for roughly 15% of the newly diagnosed adult leukemias. Prognosis has improved...

Subtotal versus total splenectomy in children with sickle cell disease: Clinical outcomes and splenic function assessed by pocked red blood cell count

Alma Al Sibaaie, Abdoulaye Sissoko, Carmen Capito et al. Nov 03, 2025 pp. 2953-2953 10.1182/blood-2025-2953

Abstract Background: The spleen is one of the first organs affected by sickle cell disease (SCD). While splenectomy may be indicated in some...

Role of genetic testing in diagnosing patients with severe congenital neutropenia: Results from PATH4WARD genetic testing program

Jolan Walter, Tricia Gooljarsingh, Henry Wu et al. Nov 03, 2025 pp. 4771-4771 10.1182/blood-2025-4771

Abstract Patients with suspected severe congenital neutropenia (SCN) frequently exhibit a wide spectrum of clinical manifestations, which ca...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page